Communiqués Zentalis Pharmaceuticals, Inc.

Actions

ZNTL

US98943L1070

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 02/09/2026			Varia. 5j.	Varia. 1 janv.
3,770 ^USD	+1,62 %		-3,08 %	+179,26 %

20/08	Zentalis Pharmaceuticals : un initié achète des actions pour une valeur de 15 172 500 $, selon une récente déclaration à la SEC	MT
17/08	Zentalis Pharmaceuticals clôture son augmentation de capital par actions ordinaires	MT

Communiqués

02/09	Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences	AQ
01/09	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
18/08	Zentalis Pharmaceuticals Announces Closing of Underwritten Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares	AQ
17/08	Zentalis Pharmaceuticals Announces Closing of Underwritten Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares	AQ
17/08	Zentalis Pharmaceuticals Announces Pricing of Underwritten Public Offering - August 13, 2026	AQ
14/08	Zentalis Pharmaceuticals Announces Pricing of Underwritten Public Offering	AQ
13/08	Zentalis Pharmaceuticals Announces Proposed Underwritten Public Offering	AQ
07/08	Zentalis Pharmaceuticals : Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q)	PU
06/08	Zentalis Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Updates	AQ
03/08	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
20/07	Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026	AQ
17/07	Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026	AQ
01/06	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
27/05	Zentalis Strengthens Commercial Leadership with Appointments of Shannon Campbell to Board of Directors and Sarah Kelly as SVP of Commercial Strategy	AQ
21/05	Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026	AQ
13/05	Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences	AQ
12/05	Zentalis Pharmaceuticals Reports First Quarter 2026 Financial Results and Clinical Progress	AQ
05/05	Zentalis Pharmaceuticals Announces First Patient Dosed in ASPENOVA Phase 3 Trial of Azenosertib in Patients with Cyclin E1-Positive Platinum-Resistant Ovarian Cancer	AQ
04/05	Zentalis Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(4)	AQ
01/05	Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	AQ
21/04	Zentalis Pharmaceuticals Announces Abstract Acceptance at ASCO 2026 Featuring Azenosertib in Combination with Paclitaxel for Platinum-Resistant Ovarian Cancer	AQ
17/04	Zentalis Pharmaceuticals To Present Azenosertib Preclinical Data in Triple-Negative Breast Cancer and Real-World Analysis of Unmet Need in Cyclin E1-Positive Ovarian Cancer at AACR 2026	AQ
09/04	Zentalis Pharmaceuticals Announces 400mg QD 5:2 Azenosertib Monotherapy as the Pivotal Study Dose in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer	AQ
01/04	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
26/03	Zentalis Pharmaceuticals Reports Full Year 2025 Financial Results and Operational Updates	AQ